<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20120814010599N25</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-01-24</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Effect of the ultrasound-guided erector spinae plane block on the degree of  post laparoscopic cholecystectomy pain</public_title>
      <acronym></acronym>
      <scientific_title>Investigation of the Ultrasound-guided erector spinae plane block effect on the degree of the post laparoscopic cholecystectomy pain</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-02-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>62</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/37231</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization will conduct based on permuted block randomization method. Each block will have capacity for 4 subjects; it means we will have 15 blocks and also one block of 2 patients (Totally 62 patients). Then, within each block, subjects will be randomly assigned to intervention or control group . Random assignment will be done using a random number table, Blinding description: In this study, a single-blind technique in which the person recording the information has no idea regarding the control or case group is used.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Laparoscopic cholecystectomy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:After the operation, upon arrival the patient to the recovery unit and monitoring, the patient is positioned left laterally, the right side is prep and drep, the probe of sonography is located longitudinally at the level of T7 (lower border of scapula) and after determination the lower and upper transverse processes, the needle is inserted in plane toward the erector spinae plane muscle. 20 cc Ropivacaine 0/2% is injected into the fascia of erector spinae plane muscle (behind the transverse process). A PCIA pomp containing 12 cc fentanyl in 100 cc (6microgram pro 1 cc) is connected to patient in both groups. The flow of the pomp will be zero and the use of the bolus bottom is instructed to the patient. (bolus = 2 cc) the patient is delivered 12-mcg of fentanyl each time the pump is pressed (in one hour at most 48-mcg fentanyl). Intervention 2: Control group: After the operation, upon arrival the patient to the recovery unit and monitoring, a PCIA pomp containing 12 cc fentanyl in 100 cc (6microgram pro 1 cc) is connected to patient. The flow of the pomp will be zero and the use of the bolus bottom is instructed to the patient. (bolus = 2 cc) the patient is delivered 12-mcg of fentanyl each time the pump is pressed (in one hour at most 48-mcg fentanyl).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is It is not clear yet.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Poupak Rahimzadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Rasoul Akram Hospital, Mansouri St., Niyayesh Ave., Satarkhan St.</address>
        <city>Tehran</city>
        <country1>Azerbaijan</country1>
        <zip>1445613131</zip>
        <telephone>02164352493</telephone>
        <email>p-rahimzadeh@tums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Poupak Rahimzadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Rasoul Akram Hospital, Mansouri St., Niyayesh Ave., Satarkhan St.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1445613131</zip>
        <telephone>+98 21 6435 2493</telephone>
        <email>p-rahimzadeh@tums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>patients with ASA =&lt; 2
patients with the age of 20-65 years old under laparoscopic cholecystectomy</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Emergent patients
History of allergy to Ropivacain
Patients received analgesic during the last 24 hours
Patients with BMI &gt; 35
Patients with liver disease, renal disease and coagulopathy or a history of it
Changing the plan of the surgery from the laparoscopy to the open cholecystectomy or occurrence of any problem during the operation</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K80.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Calculus of gallbladder with acute cholecystitis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:After the operation, upon arrival the patient to the recovery unit and monitoring, the patient is positioned left laterally, the right side is prep and drep, the probe of sonography is located longitudinally at the level of T7 (lower border of scapula) and after determination the lower and upper transverse processes, the needle is inserted in plane toward the erector spinae plane muscle. 20 cc Ropivacaine 0/2% is injected into the fascia of erector spinae plane muscle (behind the transverse process). A PCIA pomp containing 12 cc fentanyl in 100 cc (6microgram pro 1 cc) is connected to patient in both groups. The flow of the pomp will be zero and the use of the bolus bottom is instructed to the patient. (bolus = 2 cc) the patient is delivered 12-mcg of fentanyl each time the pump is pressed (in one hour at most 48-mcg fentanyl).</i_keyword>
      <i_keyword>Control group: After the operation, upon arrival the patient to the recovery unit and monitoring, a PCIA pomp containing 12 cc fentanyl in 100 cc (6microgram pro 1 cc) is connected to patient. The flow of the pomp will be zero and the use of the bolus bottom is instructed to the patient. (bolus = 2 cc) the patient is delivered 12-mcg of fentanyl each time the pump is pressed (in one hour at most 48-mcg fentanyl).</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The degree of the pain based on the Numerical Rating Scale criterion. Timepoint: 0 means at the time of arrival to the recovery, 20 minutes after the implementation of the block, 2, 4, 6, 12, and 24 hours after the surgery. Method of measurement: The degree of the pain based on the Numerical Rating Scale criterion.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>The amount of the opioid used during the first 24 hours after the surgery in milligrams. Timepoint: 0 means at the time of arrival to the recovery, 20 minutes after the implementation of the block, 2, 4, 6, 12, and 24 hours after the surgery. Method of measurement: Based on the amount of the used opioid reported by the person recording the information in the questionnaire in milligrams.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-12-23</approval_date>
        <contact_name>Ethics committee of Iran University of Medical Sciences</contact_name>
        <contact_address>Vice-chancellor for research and technology of Iran University of Medical Sciences, Shahid Hemmat Highway, Tehran, IRAN Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
